Viiv Healthcare launches Triumeq in Japan
Viiv Healthcare, the joint HIV venture by GlaxoSmithKline (LSE: GSK), Pfizer (NYSE: PFE) and Shionogi (TYO: 4507), has launched Triumeq (abacavir, dolutegravir and lamivudine) in Japan.
Triumeq was approved by the Ministry of Health, Labor and Welfare for the treatment of HIV infection on March 16, 2015. It is being co-promoted by Viiv and Shionogi, with distribution and sales operations carried out by GSK.
It is the company’s first fixed-dose combination tablet for a once-daily single-pill regimen combining dolutegravir, an integrase inhibitor, with the nucleoside reverse transcriptase inhibitors abacavir and lamivudine. Triumeq received FDA approval in August 2014. Dolutegravir, one of the drug’s three active ingredients, was approved as Tivicay on March 24, 2014 and launched on April 17 of the same year, with Viiv and Shionogi co-promoting the product.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze